" class="no-js "lang="en-US"> Alex Therapeutics - Medtech Alert
Thursday, August 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Alex Therapeutics | Pharmtech Focus

Alex Therapeutics

About Alex Therapeutics

Alex Therapeutics

At Alex Therapeutics, we develop CE-certified Digital Therapeutics (DTx) products.

We are a pioneer within our field, combining Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with Artifical Intelligence to provide our patients with highly personalized and effective care.

Our first product, Alex AI – Quit Smoking, combines CBT with AI to help patients treat Nicotine Addiction. So far over 100,000 patients have chosen Alex AI to help them overcome their Nicotine Addiction.

The Alex Platform allows for the easy development of new products and we see incredible potential in future verticals such as obesity, depression, oncology and more.

We’re always looking for great new partners and co-workers. Send us an email at hello@alextherapeutics.com to get in touch.

Related Story

Clinical Trials

 Alex Therapeutics Raises €3.5M in Oversubscribed Financing round from Top Tier VC Investors to Advance Expansion in Europe and the US. | Pharmtech Focus

Alex Therapeutics Raises €3.5M in Oversubscribed Financing round from Top Tier VC Investors to Advance Expansion in Europe and the US.

April 6 2022

Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics today announces it has secured a €3.5M funding round, led […]

Industry News

 Pfizer and Alex Therapeutics Announce a Strategic Commercial Partnership to Provide Evidence-based Digital Therapeutics to Patients

Pfizer and Alex Therapeutics Announce a Strategic Commercial Partnership to Provide Evidence-based Digital Therapeutics to Patients, Starting in Germany

January 31 2022

The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined […]